

-2-

Amendments to the Claims

Please amend Claims 1, 4, 5 and 7. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently amended) A CD4-specific chimeric immunoglobulin or chimeric antigen binding fragment thereof, said immunoglobulin or fragment having the epitopic specificity of monoclonal antibody M-T412 and comprising the variable region of monoclonal antibody M-T412 (produced by the cell line ATCC® Accession No. PTA-6196) and at least a portion of a constant region of human origin.
- 2-3. (Canceled)
4. (Currently amended) A CD4-specific chimeric immunoglobulin fragment, wherein said fragment has the epitopic specificity of monoclonal antibody M-T412 and comprises the variable region of monoclonal antibody M-T412 (produced by the cell line ATCC® Accession No. PTA-6196) and at least a portion of a constant region of human origin.
5. (Currently amended) A chimeric immunoglobulin or chimeric antigen binding fragment thereof, wherein said immunoglobulin or fragment is specific for CD4, has the epitopic specificity of monoclonal antibody M-T412, and comprises:
 - a) at least one chimeric heavy chain comprising the heavy chain variable region of monoclonal antibody M-T412 (produced by the cell line ATCC® Accession No. PTA-6196) linked to at least a portion of a human heavy chain constant region, the heavy chain being in association with:
 - b) at least one chimeric light chain comprising the light chain variable region of monoclonal antibody M-T412 (produced by the cell line ATCC® Accession No. PTA-6196) linked to at least a portion of a human light chain constant region.
6. (Canceled)

-3-

7. (Currently amended) A chimeric immunoglobulin Fab, Fab' or F(ab')₂ fragment which has the epitopic specificity of monoclonal antibody M-T412 and comprises the variable region of monoclonal antibody M-T412 (produced by the cell line ATCC® Accession No. PTA-6196) and a human constant region.
- 8-12. (Canceled)
13. (Withdrawn) A method of therapy for an autoimmune disorder, comprising administering to a patient a therapeutically effective amount of a CD4-specific chimeric immunoglobulin or chimeric antigen binding fragment of Claim 1.
- 14-15. (Canceled)
16. (Withdrawn) The method of Claim 13, wherein a chimeric antigen binding fragment is administered.
17. (Withdrawn) The method of Claim 16, wherein the chimeric antigen binding fragment is an Fab fragment, Fab' fragment or F(ab')₂ fragment.
18. (Canceled)
19. (Previously presented) A CD4-specific chimeric immunoglobulin fragment of Claim 4, wherein said fragment is an Fab fragment, Fab' fragment or F(ab')₂ fragment.
20. (Previously presented) A chimeric immunoglobulin or chimeric antigen binding fragment of Claim 5, which is an Fab fragment, Fab' fragment or F(ab')₂ fragment.